Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused - Endpoints News

As reported by Endpoints.news

Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Endpoints.news ↗

Market Samachar is a news aggregator. This article was originally published by Endpoints.news. Tap the button above to read the full story on their site.

INDIAN NSE SME Sumax Engineering makes a polished debut but struggles to accelerate Share Market Today
INDIAN Sai Life Science surges 8% in two days; stock hits new high in weak market Share Market Today
INDIAN Volumes soar at Havells India Ltd counter Share Market Today
INDIAN Coal India rallies 4% on huge volume amid Mahanadi Coalfields IPO buzz Share Market Today
INDIAN Stock Market LIVE: Sensex falls 600 pts, Nifty near 23,800; India VIX rises 5% Share Market Today
INDIAN Every time FIIs panicked, here's what happened next - Nikhil Kamath explains why smart foreign money isn't always right mint - markets
INDIAN Up to 40% returns? Looking for top stock picks for Sept 2026? Axis Securities shares list of 15 | Upside, target price mint - markets
CRYPTO HYPE treasury firm Hyperliquid Strategies boosts equity facility to $2.5B Cointelegraph.com News

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused - Endpoints News

More from Market Samachar